examining the role of s potential for mindful and as in the Our fi ndings that patients ’ mindful and autonomous decision-making can be a in facilitating the fl ow from compliance to adherence. However, an established physician-patient partnership based on can mitigate the of mindful Thus, given that are and and is essential to promoting Mindful nonadherence is less likely to occur when treatment coincides with ’ beliefs and needs. These fi ndings help health researchers and practitioners better understand how to lead active, persistent self-care (adherence) from the passive following of treatment These data support strategies looking at increasing physical activity levels to improve CRF and avoid the development of excess abdominal obesity and excess weight We examined how attitudes, perceived community norms, and prior related behaviors predict intentions to receive COVID-19 vaccination and practice social distancing. Using cross-sectional data from an online survey ( N = 1,804), we found that 30% of respondents reported a strong willingness to receive COVID-19 vaccination, while 67% strongly intended to engage in social distancing. Vaccination intention was predicted by positive vaccine attitudes (b = 0.84; 95%CI: 0.78, 0.90; P < .001), prior in fl uenza vaccination (b = (cid:1) 0.47; 95%CI: -0.63, -0.32; P < .001), and community norms (b = (cid:1) 0.28; 95%CI: -0.56, -0.01; P = .049). Intention to practice social distancing was predicted by positive attitudes (b = 0.65; 95%CI: 0.61, 0.69; P < .001), prior social distancing (b = (cid:1) 0.49; 95%CI: -0.59, -0.39; P < .001), and community norms (b = (cid:1) 0.28; 95%CI: -0.46, -0.09; P = .003). Targeting and tailoring messages on pre-existing attitudes, prior related behaviors, perceived community norms, and sociodemographic factors may improve communication strategies to promote protective health behaviors Lung cancer screening (LCS) with low-dose CT (LDCT) reduces lung cancer mortality but is infrequently conducted in eligible patients. The purpose of this study was to describe barriers to LCS among primarycare physicians (PCPs) and assess the association of barriers with discussion and referral for screening. We surveyed PCPs across practice settings in California and grouped barriers into four categories: (1) Physician Visit-Level Barriers; (2) Physician System and Evidence Barriers; (3) Patient Cost Barrier; and (4) Other Patient Barriers. While physicians endorsed numerous barriers to LCS, we found that barriers were differentially associated with discussion or referral for screening. Physician-reporting of System and Evidence Barriers was associated with lower odds of discussion or referral for LDCT, while Visit-Level Barriers were associated with increased odds discussion or referral. As new LCS guidelines broaden screening eligibility, it is critical to address these barriers to achieve higher rates of evidence-based LCS part of a multi-agency capacity building effort, we conducted a survey of workplace stakeholders and leaders of various sized organizations to assess the prevalence and impact of mental health-related problems on lost productivity, and of programs implemented to mitigate risks. Results indicate that while leaders in smaller organizations report less exposure to mental health-related concerns they become increasingly vulnerable as MHR concerns accumulate. Financial costs of MHR problems are also provided
Alex Perry and I established Th eoretical & Applied Ethics with a primary goal of ensuring that the journal would grow up squarely within the scholarly world but be spared the negative infl uences that aff ect so many other journals. We wanted to showcase the best work in ethics while not becoming stuck in the mainstream, and we wanted to break away from the traditional way of interacting with authors, who aft er all are the lifeblood of any journal. In these and other ways, we hoped that t&ae would be seen as traditional yet progressive at the same time. What we did not realize, and to be honest, were not prepared for, was the prospect that any of this would actually work. When it became clear that we were receiving more submissions and suggestions for future thematic issues than we could adequately address, Alex and I began to search for more journal staff and an academic publisher. Aft er more than a year of negotiations with various publishers, we decided to partner with the University of Nebraska Press. Not only did Nebraska ensure us that we would be able to maintain our slightly counterculture perspective, the Press has off ered very useful advice on how we might handle our future growth. Th e fact that the state of Nebraska holds a special place in our hearts helped to seal the deal. Th ank you to the Press, the authors who contributed to this issue, and the readers who support their eff orts and ours.
Following an acute myocardial infarction (MI), ACE inhibitor therapy improves ventricular function, prolongs survival and decreases infarct size. Currently, ACE inhibitors are not indicated for use in the prevention of ischaemia in patients with coronary artery disease (CAD). However, evidence is mounting to suggest that quinapril may find a use in this indication. Results from a 1-year follow-up of the QUinapril On Vascular Ace and Determinants of ISchaemia (QUO VADIS) study suggest that long-term ACE inhibition with quinapril reduces ischaemic events in patients who have undergone coronary artery bypass graft (CABG) surgery. These beneficial effects may be unrelated to the BP-lowering effects of quinapril, delegates were told at the 71st Scientific Sessions of the American Heart Association [ Dallas, US; November 1998 ].
The increasing resistance of micro-organisms to antimicrobial agents is a major public health problem. Previously well controlled diseases have become difficult to treat due to the rapid or sustained emergence of bacterial resistance. Dr Stuart Levy from Tufts University, Boston, US, told delegates at the 99th General Meeting of the American Society for Microbiology [ Chicago, US; May-June 1999 ], that overprescribing of antimicrobials, public expectation of the need for antimicrobials for nonbacterial infections, excessive use of antimicrobials in animal food production and the widespread use of cleansing products impregnated with antimicrobials are largely responsible for this problem.
While HIV has undoubtedly been the viral focus of attention in recent years, hepatitis C virus (HCV) is now forcing its way onto the world’s healthcare stage. The new attention that HCV has received since the beginning of the year is well deserved - this virus infects 5 times as many people as HIV worldwide. One reason for this is that no effective screening test existed for HCV, which is transmitted via the blood, prior to 1986 and it took an additional 6 years to develop a reliable blood test. Thus, vast numbers of individuals joined the ranks of infected patients via transmission of tainted blood products. Consequently, millions of people are now moving through the natural course of the disease at varying speeds, and in an effort to divert catastrophe, researchers and clinicians are hurriedly trying to apply the therapeutic lessons learned from HIV to HCV. The potential market size for therapeutic intervention is huge and it is no surprise that several major pharmaceutical and biotechnology companies are involved in what has become an extremely competitive field.
